Literature DB >> 414269

Dopaminergic agonist properties of ephedrine--theoretical implications.

B Angrist, J Rotrosen, D Kleinberg, V Merriam, S Gershon.   

Abstract

Reports of ephedrine-induced psychoses resembling amphetamine psychosis prompted studies of this classic sympathomimetic agent in systems that indicate central dopaminergic actions. Ephedrine induced dose-related stereotyped behavior in rats. This behavior was antagonized by haloperidol, but not by alpha- or beta-adrenergic blockers. Pretreatment with AMPT, but not reserpine, attenuated the stereotypy induced by ephedrine under one of two sets of conditions. Consistent prolactin suppression in humans was not seen. These findings are discussed in the context of clinical and pharmacologic data regarding other dopamine agonist drugs (the central nervous system stimulants, apomorphine, ET 495). These data suggest the possibility that synergistic noradrenergic and dopaminergic facilitation may be important in the induction of the stimulant psychoses.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 414269     DOI: 10.1007/bf01457845

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  20 in total

1.  IS IT POSSIBLE TO PREDICT THE CLINICAL EFFECTS OF NEUROLEPTIC DRUGS (MAJOR TRANQUILLIZERS) FROM ANIMAL DATA?I. "NEUROLEPTIC ACTIVITY SPECTRA" FOR RATS.

Authors:  P A JANSSEN; C J NIEMEGEERS; K H SCHELLEKENS
Journal:  Arzneimittelforschung       Date:  1965-02

2.  A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat brain.

Authors:  D M Jackson; N E Andén; A Dahlström
Journal:  Psychopharmacologia       Date:  1975-12-31

Review 3.  Studies on prolactin in man.

Authors:  A G Frantz; D L Kleinberg; G L Noel
Journal:  Recent Prog Horm Res       Date:  1972

4.  Effect of apomorphine and pimozide on synthesis and turnover of labelled catecholamines in mouse brain.

Authors:  H Nybäck; J Schubert; G Sedvall
Journal:  J Pharm Pharmacol       Date:  1970-08       Impact factor: 3.765

5.  Effect of apomorphine on motility in rats.

Authors:  J Maj; M Grabowska; L Gajda
Journal:  Eur J Pharmacol       Date:  1972-02       Impact factor: 4.432

6.  Psychosis accompanying use of bronchodilator compound.

Authors:  F J Kane; R Florenzano
Journal:  JAMA       Date:  1971-03-29       Impact factor: 56.272

7.  Ephedrine psychosis.

Authors:  C F Herridge; M F a'Brook
Journal:  Br Med J       Date:  1968-04-20

8.  An anatomy of schizophrenia?

Authors:  J R Stevens
Journal:  Arch Gen Psychiatry       Date:  1973-08

9.  Clinical studies with dopamine-receptor stimulants.

Authors:  B Angrist; H Thompson; B Shopsin; S Gershon
Journal:  Psychopharmacologia       Date:  1975-11-21

10.  Dopamine receptor alteration in schizophrenia: neuroendocrine evidence.

Authors:  J Rotrosen; B M Angrist; S Gershon; E J Sachar; F S Halpern
Journal:  Psychopharmacology (Berl)       Date:  1976-12-21       Impact factor: 4.530

View more
  5 in total

1.  Banned, but Not Forgotten: A Case of Ephedrine-Induced Psychosis.

Authors:  Thomas J. Kim; H W LeBourgeois
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

2.  The effect of dopamine and noradrenaline blockade on amphetamine-induced behaviour in the marmoset.

Authors:  P R Scraggs; R M Ridley
Journal:  Psychopharmacology (Berl)       Date:  1979-03-29       Impact factor: 4.530

3.  Dopamine-like properties of ephedrine in rat brain.

Authors:  M R Zarrindast
Journal:  Br J Pharmacol       Date:  1981-09       Impact factor: 8.739

4.  Factors influencing the reinforcing and subjective effects of ephedrine in humans.

Authors:  L D Chait
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

Review 5.  In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine.

Authors:  Antonio Munafò; Stefano Frara; Andrea Giustina; Renato Bernardini; Norberto Perico; Rosaria Di Mauro; Monica Cortinovis; Chiara Burgaletto; Giuseppina Cantarella; Giuseppe Remuzzi
Journal:  Rev Endocr Metab Disord       Date:  2021-05-04       Impact factor: 6.514

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.